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Abstract: Chitosan nanoparticles are good drug carriers because of their good biocompatibility 
and biodegradability, and can be readily modified. As a new drug delivery system, they have 
attracted increasing attention for their wide applications in, for example, loading protein drugs, 
gene drugs, and anticancer chemical drugs, and via various routes of administration including 
oral, nasal, intravenous, and ocular. This paper reviews published research on chitosan nano-
particles, including its preparation methods, characteristics, modification, in vivo metabolic 
processes, and applications.
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Introduction
Many drugs have problems of poor stability, water insolubility, low selectivity, high 
toxicity, side effects, and so on. Good drug carriers play a significant role in   resolving 
these problems. Chitosan nanoparticles are a drug carrier with wide development 
potential and have the advantage of slow/controlled drug release, which improves 
drug solubility and stability, enhances efficacy, and reduces toxicity. Because of their 
small size, they are capable of passing through biological barriers in vivo (such as 
the blood–brain barrier) and delivering drugs to the lesion site to enhance efficacy.1 
Modified nanoparticles also have other properties such as improved drug   targeting. 
Under the action of enzymes in vivo, biodegradable nanoparticles can produce water 
and carbon dioxide without adverse effects, and have thus become the focus of 
  increasing research.
As a copolymer containing β-(1,4)-2-acetamido-D-glucose and β-(1,4)-2-amino-
D-glucose unit (Figure 1), chitosan is produced by removing an acetate moiety from 
chitin through hydration in concentrated alkali. Chitosan is soluble in most diluted 
acids. Under acidic conditions, chitosan can be dissolved in water after amino proto-
nation to confer positive charges, gelation, and membrane-forming properties. The 
glycosidic bond of chitosan is hemiacetal, and thus is not stable in acid and will be 
hydrolyzed under acidic conditions, resulting in decreased viscosity and molecular 
weight of chitosan. Physical and chemical properties of chitosan depend mainly on 
its molecular weight and degree of deacetylation.2 As a natural product, chitosan is a 
renewable pharmaceutic adjuvant with good biocompatibility. Chitosan and its deriva-
tives have strong potential for application as drug carriers.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Basic characteristics of chitosan
Adhesivity of chitosan
The amino and carboxyl groups in the chitosan molecule can 
be combined with glycoprotein in mucus to form a hydrogen 
bond, leading to an adhesive effect. As mucoprotein in mucus 
is positively charged, chitosan and mucus are attracted to each 
other to prolong the retention time of drugs and continuous 
drug release in vivo as well as improve drug bioavailability.2 
Dudhani and Kosaraju,3 who prepared chitosan nanoparticles 
encapsulating catechin, found that encapsulated catechin had 
a release percentage of 60% under the action of enzyme. 
Release testing in vitro showed that 32% of   catechin still 
existed after 24 hours. These results indicated that adhe-
sivity of chitosan enhanced controlled release of catechin 
and improved its bioavailability.3 Adhesivity of chitosan is 
strengthened under neutral and acidic conditions. The greater 
the molecular weight and higher the degree of deacetylation 
of chitosan, the stronger will be its adhesivity and the amount 
of adhesion. Some chitosan groups (such as sulfydryl) can 
be easily modified to strengthen its adhesivity.2
Biodegradability and safety of chitosan
The biodegradability of chitosan is important for its use in 
drug delivery systems. Chitosan of suitable molecular weight 
can be cleared by the kidney in vivo, while that of excessive 
molecular weight can be degraded into fragments suitable 
for renal clearance.4
Chitosan is degraded mainly by chemical process and 
enzyme catalysis; the latter is the major in vivo process.4 The 
higher the degree of deacetylation, the greater the degradation 
rate. Degradation by enzyme catalysis also depends on the avail-
ability of chitosan’s amino group.4 At present, it is generally 
believed that chitosan is a nontoxic polymer as well as safe drug 
delivery material. It has been certified as a wound dressings 
by the US Food and Drug Administration.5 Compared with 
toxic compounds such as sulfide (LD50 , 20 µg/mL against 
MCF7 and COS7 cells), chitosan has no obvious toxicity. 
However, with increasing charge density, toxicity of chitosan 
will strengthen accordingly.4 Intravenous injection of excessive 
chitosan may cause death due to blood coagulation.4
Antitumor effect of chitosan
Chitosan can act on tumor cells directly to interfere with cell 
metabolism, inhibit cell growth, or induce cell   apoptosis. 
It also has an antitumor role through improving the body’s 
immune function.6 Maeda and Kimura7 showed that 
  low-molecular-weight chitosan and chito-oligosaccharide 
could inhibit tumor growth in S180-bearing mice. Torzsas 
et al8 found that a diet containing chitosan could reduce the 
generation of precancerous lesions in colon cancer induced 
by azomethane compounds. In vitro antitumor testing 
of chitosan nanoparticles indicated that inhibition rate of 
500 mg/L chitosan nanoparticles was 27% on Hela cells of 
cervical cancer, 23% on liver SMMC-7721 cells, 29% on 
gastric cancer BGC-823 cells, and as high as 55% on breast 
cancer MCF-7 cells.9 These studies suggested that chitosan 
had antitumor effects in vitro and in vivo, leading to good 
prospects for their application as a supplementary antitumor 
drug and drug carrier. Studies have also indicated significant 
differences in antitumor activity of nanoparticles prepared by 
chitosan from different producers, and chitosan nanoparticles 
also had a selectivity for tumor cells.10
Preparation techniques  
of chitosan nanoparticles
Ionic cross-linking
As a widely used method for preparing chitosan nanoparticles, 
ionic cross-linking is generated by auto-aggregation between 
chitosan or its derivatives and macromolecules of opposite 
charge, or when ionic cross-linking agent exists. The most com-
monly used cross-linking agent is sodium tripolyphosphate. 
When it is added continuously to a water solution of chitosan 
with constant stirring under a moderate temperature, two 
components with opposite charges will combine to form 
nanoparticles.11 In the chitosan–Arabic gelatin nanoparticles 
of insulin prepared by Avadi et al12 minimum particle size 
and maximum combining rate with insulin were reached at a 
chitosan concentration of 10 mg/mL, Arabic gelatin concentra-
tion of 5 mg/mL, and insulin concentration of 5 mg/mL.12 As 
ionic cross-linking can be performed at room temperature to 
avoid the use of organic solvent, and uniform nanoparticles with 
an adjustable size can be obtained easily, cross-linking has been 
widely used in encapsulation of protein and gene drugs. Using 
ionic cross-linking, chitosan nanoparticles were prepared by   
Du et al13 and then loaded with Ag+, Cu2+, Zn2+, Mn2+, and 
Fe2+. The zeta potential of chitosan nanoparticles is intensified 
significantly by positive charge of ions thus improving the sta-
bility of nanoparticles and greatly   enhancing the   antibacterial 
potential of nanoparticles.13
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Covalent cross-linking
Chitosan and its derivatives can be prepared as nanopar-
ticle drug carriers by using covalent cross-linking,14 which 
involves mainly the formation of covalent bonds between 
the chitosan chain and a functional cross-linking agent. This 
method was first used to prepare chitosan nanoparticles by 
encapsulating 5-fluorouracil by cross-linking glutaraldehyde 
with amino groups in the molecular chain of chitosan.15 
Commonly applied agents also include polyethylene glycol 
(PEG) dicarboxylic acid, glutaraldehyde, or monofunc-
tional agents such as epichlorohydrin.16,17 Fe3O4–chitosan 
nanoparticles were prepared by Qu et al18 by covalent cross-
linking   (Figure 2). Oleic acid-coated Fe3O4 nanoparticles are 
absorbed by chitosan and cross-linked with glutaraldehyde, 
resulting in Fe3O4–chitosan nanoparticles of average size of 
10.5 nm and a narrow size distribution. These   nanoparticles 
have been shown to have a highly saturated magnetization 
effect, superparamagnetic properties, and a sufficiently high 
  temperature to induce hyperthermia.18
Precipitation
There are two kinds of approaches for nanoparticle 
  precipitation. One is desolvation, in which flocculant 
  (commonly sodium sulfate) is added to a water solution 
of chitosan and solubility of chitosan is decreased by the 
combination of water and sodium sulfate, leading to the pre-
cipitation of nanoparticles due to hydrogen bonding between 
molecules. This method was first applied by Berthold et al19 to 
prepare chitosan microspheres. Technical improvements then 
enabled Tian and Groves20 to prepare 600- to 800-nm chitosan 
nanoparticles. The other type is based on diffusion of emulsi-
fied solvent. Under the action of emulsified solvent, the water 
phase containing chitosan is dispersed in the organic phase 
encapsulating the drug, where turbulence appears between 
the interfaces of the two phases and chitosan is precipitated, 
resulting in the generation of nanoparticles.21 In this method, 
organic solvent is used and the large nanoparticles obtained 
restricting their application.
Polymerization
Radical polymerization was initially developed by Chauvierre 
et al.22–24 It was later used to prepare chitosan and thiolated 
chitosan-poly (isobutyl cyanoacrylate) core-shell nanopar-
ticles by Bravo-Osuna et al.25 Diluted nitric acid solution 
of chitosan was stirred continuously together with a mixed 
solution of ceric ammonium nitrate, nitric acid, and isobutyl 
cyanoacrylate at 40°C for 40 minutes in an argon   environment. 
After cooling to room temperature, sodium hydroxide was 
added to adjust pH to 4.5 and a nanoparticle suspension was 
then obtained.25 Radical polymerization, by combining differ-
ent monomers, can regulate both nanoparticle shell and core 
properties. de Moura et al26 prepared chitosan–methyl acrylic 
acid (CS–PMMA) nanoparticles by polymerization through 
ionic interaction between COO− produced by   carboxyl dis-
sociation from methyl acrylic acid and the amino group of 
chitosan. It was shown in a transmission electron microscope 
micrograph that these nanoparticles were uniformly spherical 
and quite consistent in size distribution.
Self-assembly
Amphiphilic compounds dispersed in water can form 
  nanoparticles with a core-shell structure by self-assembly. 
With a hydrophobic core and a hydrophilic shell, amphiphilic 
nanoparticles can be used as carriers for hydrophobic and 
hydrophilic drugs simultaneously. The hydrophilic shell greatly 
reduces macrophage phagocytosis. Therefore, amphiphilic 
nanoparticles have attracted increasing   attention. Kim et al27 
used hydrophobic cholanic acid to modify glycol chitosan and 
then form nanoparticles by self-assembly in water solution. The 
antitumor drug cisplatin was encapsulated into the hydrophobic 
core with a drug loading of 80%.28 The amphiphilic derivatives 
of N-octyl-O, N-carboxymethyl chitosan (OCC) prepared by 
Huo et al28 enhanced the solubility of the insoluble antitumor 
drug paclitaxel. Solubility of paclitaxel was improved nearly 
500-fold with a drug   loading of 34.6% and encapsulation 
rate of 89.9%, indicating that OCC is a potentially excellent 
solubilization carrier for insoluble drugs.
Chitosan–drug complexes
Because of the cationic properties of chitosan, ion com-
plexes can be formed by electrostatic interaction between 
Glutaraldehyde
Fe3O4 Oleic acid Chitosan
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chitosan and anionic drugs. Cheng et al29 prepared chitosan 
nanoparticles linked with antisense oligonucleotide (asON). 
By the mixing method, the nanoparticles could be made 
easily under the optimal condition of 2:1 M proportion of 
chitosan phosphate and asON. The size of the nanoparticles 
was 102.6 ± 12.0 nm, their zeta potential was 1.45 ± 1.75, 
and the encapsulated ratio of chitosan cross-linked asON 
was 87.6 ± 3.5%. Kim et al30 encapsulated retinol into 
chitosan nanoparticles through the electrostatic interaction 
between the amine group of chitosan and the hydroxyl 
group of retinol. Encapsulation into chitosan nanoparticles 
was shown to increase solubility of retinol by more than 
1600-fold.
Spray-drying
Spray-drying method can be used as a one-step preparation 
of nanoparticle powder. Grenha et al31 prepared mannitol 
microspheres containing chisosan nanoparticles-loaded 
protein by this method. Huang et al32 prepared chitosan–
iron oxide nanoparticles with various chitosan:iron oxide 
ratios by spray-drying. Atomic absorption spectrometry 
results implied that chitosan had strong chelation with iron. 
  Meanwhile, Fe3O4 was crystallized and distributed in the 
chitosan matrix. These chitosan–iron oxide nanoparticles 
were stable in water with strong superparamagnetism.
Characteristics of chitosan 
nanoparticles
General characteristics
Nanoparticles are solid colloid particles of 1 to 1000 nm. 
Compared with micron-grade particles, nanoparticles have 
strong mobility because of their small size and can enter 
cells easily to accumulate at the lesion site. Therefore, cell 
uptake rate is high.33
Characteristics of sustained/controlled 
release
Drugs carried by chitosan nanoparticles can be released 
through degradation and corrosion of chitosan, leading to a 
clear sustained-release effect. Because of varied degradation 
rate and time of chitosan of different molecular weight and 
degree of deacetylation degree, different types of nanopar-
ticles can be used to regulate drug-release rate. Meanwhile, 
chitosan can also be modified to achieve the sustained/
controlled release. Chitosan–alumino-silicate nanoparticles 
prepared by Yuan et al34 had significant sustained/controlled-
release effects. pH of the environment and chitosan:alumino-
silicate ratio also influence drug release.
Targeting of chitosan nanoparticles
Positive charges of chitosan have selective adsorption and 
neutralizing effects on the tumor cell surface. As a drug 
carrier, it has a targeting function to liver, spleen, lung, 
and colon.35 Ethylene chitosan nanoparticles had a pro-
longed circulating time in the blood with a high tumor-cell 
  selectivity.36 Moreover, this kind of effect was more obvious 
in ethylene chitosan nanoparticles of large molecular weight. 
Doxorubicin–chitosan polymeric micelles had excellent 
drug-loading properties, were suitable for targeting the liver 
and spleen, and significantly reduced drug toxicity to the 
heart and kidney.37
Modification of chitosan 
nanoparticles
In order to improve targeting and bioavailability of chitosan 
nanoparticles, an increasing number of studies are focusing 
on modification of chitosan. Modified chitosan nanoparticles 
are characterized by pH sensitivity, thermosensitivity, and 
targeting accuracy.
Modification of pH sensitivity
A pH-sensitive nanocarrier is a drug delivery system that 
increases drug release by changing carrier properties under a 
certain acid-base environment in vivo, and targets the lesion 
tissue. Poly(propyl acrylic acid) (PPAA) is a polymer that 
is highly sensitive to pH. At a pH lower than 6.0, its high 
membrane fragmentation ability was shown to cause rupture 
of endosomal membrane and release vesicular materials 
into cytochylema.38 Therefore, Kiang et al39 added PPAA 
to chitosan–DNA complex to improve gene transfection 
efficiency. The results showed that adding PPAA to chitosan–
DNA complexes enhanced gene expression in both HEK293 
and HeLa cells compared with chitosan nanoparticles alone. 
Camptothecine-loaded N-isopropylacrylamide–chitosan 
nanoparticles were sensitive to pH: the nanoparticles were 
most sensitivite to tumor pH when the charge ratio of 
N-isopropylacrylamide:chitosan was 4:1.40 At a pH of 6.8, 
cumulative release rate of camptothecine was highest and cell 
toxicity was significantly stronger. Cell toxicity was mini-
mum at a pH of 7.4. Thus, N-isopropylacrylamide–chitosan 
nanoparticles have a good potential for use as a targeted 
anticancer drug carrier.40 Chitosan nanoparticles prepared 
with sodium tripolyphosphate and glycidoxypropyltrimethox-
ysilane cross-linking were pH sensitive.41 With antihuman 
IgG antibody as a model protein drug, the release of antibody 
was increased from 5.6% to 50% when solution pH was 
adjusted from 7.4 to 6.0. Therefore, chitosan nanoparticles International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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prepared by two-step cross-linking are a potential drug carrier 
sensitive to pH.41
Modification of thermosensitivity
Drug release is regulated by structural change of ther-
mosensitive drug carriers at different temperatures. 
  Poly(N-isopropylacrylamide) is a well-known thermosen-
sitive polymer widely used in drug carriers.42,43 Chitosan–
polyvinylcaprolactan graft copolymer nanoparticles were 
sensitive to temperature, with a critical solution temperature 
at 38°C.44 With 5-fluorouracil as a model drug, drug release 
mainly occurred above 38°C with high toxicity to tumor cells 
but low toxicity to normal cells.
Modification of targeting
Active targeting can be obtained in chitosan nanoparticles 
through chemical modification, so as to make the drug 
identify the target accurately. With resveratrol as a model 
drug, Yao45 prepared chitosan nanoparticles using ligands 
of both avidin and biotin to modify the nanoparticles. The 
resulting delivery system passively targeted the liver and 
positively targeted hepatoma cells. Two kinds of targeting 
mechanisms were thus combined in the new drug delivery 
system to achieve targeting to specific cells in specific 
  tissues, further improving therapeutic effects and reducing 
toxic and side effects.45 Chitosan nanoparticles modified 
by   glycyrrhizic acid, strengthened the active liver-targeting 
delivery of drug-loaded carriers through the mediation of 
glycyrrhizic acid because there were binding sites of glycyr-
rhizic acid on the surface of liver parenchyma.46 Kim et al27 
used hydrophobic cholanic acid to modify glycol chitosan   
and prepare nanoparticles through self-assembly. The 
antitumor drug cisplatin could be encapsulated easily in a 
hydrophobic core of nanoparticles. It was proven that due 
to prolonged circulating time in vivo and strengthened cell 
permeability and drug effect, drug-loaded nanoparticles 
were concentrated in tumor tissues of mice successfully 
with better antitumor effect and lower toxicity.27 Min et al47 
used chemical binding to bind hydrophobic 5β-cholanic 
acid with the skeleton of hydrophilic glycol chitosan 
(HGC) to prepare nanoparticles. Using a dialysis method, 
camptothecine could be encapsulated into the nanoparticles 
easily, with drug-loading of more than 80%. Camptothecine 
(CPT) was effectively protected from hydrolyzation by the 
hydrophobic core of HGC nanoparticles under a physi-
ological environment, producing CPT-HGC nanoparticles 
with a significant antitumor effect and high targeting to 
MDA-MB231 human breast cancer cells.47 Hydrophobic 
glycol chitosan nanoparticles were shown to be excellent 
carriers for insoluble antitumor drugs.
In vivo metabolic process  
of chitosan nanoparticles
Nanoparticles are recognized as foreign matter in vivo and are 
absorbed by antibodies generated in the human body. Plasma 
protein, lipoprotein, immune protein, and   complement 
C protein in plasma are also adsorbed on nanoparticles, 
accelerating the reorganization of the reticuloendothelial 
system. Nanoparticles are engulfed by macrophage and 
cleared from the body’s circulation.48 The bridge between 
nanoparticles and macrophage is formed because of plasma 
protein adsorbed on the nanoparticle surface. The ability 
of nanoparticles to adsorb plasma protein is determined 
by surface charge of nanoparticles, thereby influencing 
the transfer intensity of nanoparticles by macrophage.49 
  Nanoparticles with polarity and high surface potential as 
well as amphipathic or hydrophilic nanoparticles are engulfed 
less and have a longer circulating time in vivo. Nam et al50 
found that glycol–chitosan nanoparticles after hydrophobic 
modification are more distributed in all cells compared with 
unmodified nanoparticles.
Drug-loaded chitosan nanoparticles are decomposed into 
free chitosan and drug in vivo. Drugs enter cell and targeted 
tissues to generate therapeutic effects. Chitosan is mainly 
degraded under catalysis of lysozyme and bacterial enzyme in 
the colon. The chitosan absorbed into blood is cleared by the 
kidney and the rest is discharged through excrement. Degree 
of deacetylation as well as molecular weight also influence 
degradation rate and degree of chitosan in vivo.51,52
Application of chitosan 
nanoparticles
Studies have shown that chitosan nanoparticles can carry many 
drugs including gene drugs, protein drugs,   anticancer chemical 
drugs, and antibiotics, and via various routes of administration 
including oral, nasal, intravenous, and ocular.
Carrier for various drugs
Carrier of gene drugs
As a gene carrier, conventional virus has the disadvantages 
of low transfection rate and cell toxicity,53 and even causes 
serious immune response. As a nonvirus carrier, chitosan 
has excellent biocompatibility and biodegradation, which 
has led to increasing application of chitosan nanoparticles 
in gene drug delivery.54,55 Gene silencing mediated by 
double-stranded small interfering RNA (siRNA) has been International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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widely investigated as a potential therapeutic approach for 
diseases caused by genetic defects.54 However, its application 
is restricted by rapid degradation and poor cell absorption. 
Drug loading of chitosan nanoparticles prepared by ionic 
gelation by Katas and Alpar54 reached 100%, protecting well 
siRNA from nuclease degradation. With natural positive ion 
chitosan as a carrier material and using electrostatic interac-
tion of polyelectrolyte, siRNA of silencing green fluorescent 
protein was compounded directly by Liu55 to prepare stable 
siRNA nanoparticles with a complex rate of 83% to 94%. It 
was also found that more stable nanoparticles with positive 
surface charges could be generated by siRNA and chitosan 
with high molecular weight and degree of deacetylation. The 
product was not only easily adsorbed onto the cell surface 
to increase chance of cellular endocytosis, but also could 
protect siRNA activity effectively during the transfection in 
cells to improve gene silencing efficiency. However, gene 
transfection efficiency of chitosan nanoparticles is low gen-
erally and also influenced by molecular weight, degree of 
deacetylation, the chitosan:DNA ratio, environmental pH, 
and nanoparticle preparation method.56 Improving transfec-
tion efficiency is a challenge for using chitosan nanoparticles 
as a gene carrier. Transfection efficiency of chitosan with 
different degrees of deacetylation and molecular weights 
was studied by Lavertu et al,57 who found that maximum 
transgene expression occurred when the ratio of the degree 
of deacetylation (DDA) to the molecular weight (MW) 
moves from high DDA/low MW to low DDA/high MW. 
Moreover, several chitosan–pDNA (plasmid DNA) com-
plex formulations achieved levels of transgene expression 
approaching those of the positive controls (LipofectamineTM, 
Life Technologies, Carlsbad, CA; and FuGENE® 6, Roche 
Diagnostics, Basel, Switzerland), while two optimal condi-
tions (92-10-5:1 and 80-10-10:1 [DDA-MW-N:P ratio] both 
at pH 6.5) were particularly effective, showing equivalent 
transfection efficiency compared with the best positive 
control.57 This provided a good example for the application 
of chitosan nanoparticles in gene transfection. Moreover, 
chitosan could also be modified by folic acid to improve 
transfection efficiency. Folic acid could be easily absorbed 
by cells, promoting the targeting and internalization of 
drug. Mansouri et al58 used folic acid to modify chitosan for 
improving gene transfection efficiency. They studied system-
atically the characteristics of folic acid for gene treatment, 
finding that folic acid-modified chitosan nanoparticles had 
low cell toxicity and could condense DNA effectively with 
ideal size and zeta potential. The results showed that folic 
acid-modified chitosan nanoparticles were a nonvirus gene 
carrier with a good application potential.
Carrier of protein drugs
Protein drugs can be degraded easily by enzymes in vivo 
and have poor permeability and stability as well as a short 
half-life. However, chitosan can protect protein well and 
promote the contact between drug and biomembrane, thereby 
improving bioavailability.11 Gan and Wang59 showed that 
changing the size and surface charge of chitosan–bovine 
serum albumin nanoparticles could regulate the encapsulation 
efficiency and release kinetics of bovine serum albumin, 
but it was difficult to control the burst release of protein 
of high molecular weight. Zhang et al60 used insulin and 
cationic β-cyclodextrin to form a complex encapsulated 
into alginate–chitosan nanoparticles. Binding rate and 
drug-loading amount were 87% and 9.5%, respectively, and 
cumulative release of insulin in simulated intestinal fluid 
reached 40%. Insulin was protected well in the nanoparticle 
core, avoiding the degradation in simulated gastric fluid, as 
well as the structure of insulin during release. Glycol chitosan 
nanoparticles modified by 5β-cholanic acid (HGC) and RGD 
(Arg-Gly-Asp) polypeptide were easily encapsulated into 
nanoparticles with a drug-loading amount greater than 85%.61 
RGD–HGC nanoparticles showed a one-week sustained-
release effect. RGD–HGC displayed antiangiogenic efficacy 
by inhibiting human umbilical venous cord endothelial cell 
adhesion to a βig-h3 protein-coated surface, markedly sup-
pressing bFGF-induced angiogenesis as well as decreasing 
hemoglobin content in Matrigel plugs in vivo. Therefore, 
RGD-HGC nanoparticles can inhibit tumor cell growth and 
reduce microvessel density significantly.61
Carrier of anticancer chemical drugs
Chitosan itself has a certain antitumor activity and its posi-
tive charge can neutralize the negative charge on the tumor 
cell surface, resulting in selective absorption. Thus, chitosan 
nanoparticles can increase drug concentration in the tumor 
site and improve therapeutic effects. Doxorubicin/methoxy 
PEG grafted carboxymethyl chitosan nanoparticles with 
higher cell toxicity could enter cell and inhibit tumor-cell 
proliferation effectively.62 Paclitaxel chitosan nanoparticles 
had a high encapsulation rate of 94.0% ± 16.73% with 
sustained-release effect.63 Cell toxicity testing showed that 
paclitaxel–chitosan nanoparticles had a higher toxicity than 
that of paclitaxel alone, and with a higher cell uptake rate. 
Using an evaporation method of composite microemulsion International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
771
Chitosan nanoparticles as drug carriers
solvent, Trickler et al64 combined glyceryl monooleate 
(GMO) and chitosan to prepare nanoparticles with a hydro-
phobic core and a hydrophilic shell. When encapsulated 
in the nanoparticle, paclitaxel had clear sustained-release 
characteristics; cell uptake increased four-fold and median 
lethal dose (IC50) of paclitaxel decreased 1000-fold, leading 
to a maximum reduction of the side effects of paclitaxel. 
Kim et al65 linked 5β-cholanic acid to the main chain of 
glycol chitosan for the preparation of amphiphilic HGC 
nanoparticles. Encapsulated into nanoparticles by the dialysis 
method, paclitaxel had a drug-loading amount greater than 
80%. With significant sustained-release effect, paclitaxel–
HGC nanoparticles had low toxicity to B16F10 melanoma 
cells but a clear anticancer cell effect.
Carrier of other drugs
Chitosan nanoparticles also can load other drugs including 
antivirus drugs, antiallergic drugs, and hormone drug. Hao 
and Deng66 prepared acyclovir-loaded chitosan nanoparticles 
with a drug loading of 17.8% and an encapsulation rate 
of 87.5% by an ionic cross-linking method. Li and Luan67 
prepared tranilast-loaded chitosan nanoparticles for allergic 
diseases with a particle size of 285.5 nm and an encapsula-
tion rate of 82.4%.
Routes of administration
Routes of administration of chitosan nanoparticles have 
been developed. Oral nanoparticles can protect drugs from 
degradation in the gastrointestinal tract and improve drug 
  absorption.68 Yin et al69 developed a promising vehicle for oral 
delivery. Trimethyl chitosan–cysteine conjugate   (TMC–Cys) 
was synthesized in an attempt to combine the mucoadhe-
sion- and the permeation-enhancing effects of TMC and 
thiolated polymers related to different mechanisms for oral 
absorption. The TMC–Cys nanoparticles, obtained via self-
assembly, possessed spherical morphology, uniform size, 
positive zeta potentials, and high insulin encapsulation effi-
ciency. Mucoadhesion and permeation enhancing effects of 
TMC–Cys nanoparticles were significantly higher than those 
of TMC nanoparticles. Biocompatibility assessment revealed 
lack of toxicity of TMC–Cys   nanoparticles.69 Because of poor 
stability and intestinal absorption of catechins, Dube et al70 
encapsulated (+)-catechin (C) and (−)-epigallocatechin   gallate 
(EGCg) in chitosan nanoparticles. The encapsulation sig-
nificantly enhanced intestinal absorption and the cumulative 
amounts transported after encapsulation were significantly 
higher.70 An insulin-loaded, pH-sensitive chitosan nanopar-
ticle was formulated by ionic cross-linking with hydroxypro-
pyl methylcellulose phthalate (HPMCP) as a pH-sensitive 
polymer.71 In vitro results revealed a superior acid stability 
of CS–HPMCP nanoparticles with a significant control 
over insulin release and degradation in simulated acidic 
conditions with or without pepsin. Moreover, fluorescently 
labeled   CS–HPMCP nanoparticles showed a 2- to 4-fold 
improvement in the intestinal mucoadhesion and penetra-
tion compared with CS–TPP nanoparticles.71 Amidi et al72 
investigated the potential of N-trimethyl chitosan (TMC) 
nanoparticles as a carrier system for the nasal delivery of 
proteins. TMC nanoparticles have an excellent loading capac-
ity for proteins, and a positive surface charge, suitable for 
attaching to nasal mucosa. In vivo experiments showed that 
TMC nanoparticles loaded with fluorescein isothiocyanate–
albumin, when administered in the nasal cavity, were able 
to cross the mucosal layer, be taken up by rat nasal epithelia 
and NALT cells, and transported to submucosal layers. 
TMC nanoparticles are a potential new delivery system for 
protein transport through the nasal   mucosa.72 Wang et al,73 
who prepared estradiol-loaded chitosan nanoparticles and 
investigated the levels of estradiol in blood and cerebrospi-
nal fluid in rats after intranasal administration, showed that 
estradiol levels in the cerebrospinal fluid after intranasal 
administration were significantly higher than after intrave-
nous administration. The drug targeting index (DTI) of the 
nasal route was 3.2 and drug targeting percent (DTP%) was 
68.4%.73 The combination of bioadhesion and paracellular 
transport effects has led to chitosan to be considered for the 
delivery of estradiol via the nasal cavity. Huo et al,74 who 
used N-octyl-O-glycol chitosan (OGC) as the carrier of 
paclitaxel for intravenous administration, found that OGC 
for intravenous administration had good biocompatibility 
and no toxicity. Moreover, paclitaxel-loaded OGC micelles 
had low toxicity and a higher tolerated dose. In vivo studies 
of chitosan-fluorescent nanoparticles (CS-fl) prepared for 
ocular administration showed that the amounts of CS-fl in 
cornea and conjunctiva were significantly higher for CS-fl 
nanoparticles than for a control CS-fl solution, these amounts 
being fairly constant for up to 24 hours.75
Future prospects
As a drug delivery system, chitosan nanoparticles have 
attracted increasing attention because of their good bio-
compatibility, degradability, and nontoxicity. Absorption 
and bioavailability of drug encapsulated into chitosan nano-
particles can be improved, so they can be used to deliver International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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protein drugs, gene drugs, and other drugs and can protect 
them effectively from enzyme degradation in vivo. Chitosan 
nanoparticles are now being modified for sustained/
controlled release and targeting. As the active antitumor 
components of plant drugs are being constantly discovered 
and developed, developing targeted chitosan carriers for 
sustained/controlled release plant drugs is also an area of 
future development. While great progress has been achieved 
in the application of chitosan nanoparticles as drug carriers, 
some problems remain to be resolved urgently. For example, 
chitosan has poor solubility and unmodified chitosan nano-
particles can encapsulate only some hydrophilic drugs. 
Although chitosan can be modified easily to encapsulate 
hydrophobic drugs, further investigation is required on the 
biocompatibility of modified chitosan and its derivatives. 
In conclusion, chitosan and its derivatives as drug carriers 
have potential for a wider application.
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